Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W

Slides:

Advertisements

Similar presentations

Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy Erik Wambre, PhD, Jonathan.

Advertisements

Vitamin D3 treatment of vitamin D–insufficient asthmatic patients does not alter immune cell function Brandy Reid, MS, Pierre-Olivier Girodet, MD, PhD,

Early suppression of basophil activation during allergen-specific immunotherapy by histamine receptor 2 Natalija Novak, MD, Nihal Mete, MD, Caroline.

Correlation of allergen-specific T follicular helper cell counts with specific IgE levels and efficacy of allergen immunotherapy Yin Yao, MD, Cai-Ling.

The effects of upper respiratory infection on T-cell proliferation and steroid sensitivity of asthmatics Elcio O. Vianna, MD, PhD, Jay Westcott, PhD,

Reduction of total IgE by targeted coengagement of IgE B-cell receptor and FcγRIIb with Fc-engineered antibody Seung Y. Chu, PhD, Holly M. Horton, PhD,

Delayed clinical and ex vivo response to mammalian meat in patients with IgE to galactose-alpha-1,3-galactose Scott P. Commins, MD, PhD, Hayley R. James,

Liping Xie, MD, John T. Schroeder, PhD, Jacqueline M

Akos Heinemann, MD, Gunter J. Sturm, MD, Martina Ofner, BSc, Eva M

Ibrutinib, a Bruton’s tyrosine kinase inhibitor used for treatment of lymphoproliferative disorders, eliminates both aeroallergen skin test and basophil.

Antigen-driven basophil activation is indicative of early Necator americanus infection in IgE-seronegative patients Franco H. Falcone, PhD, Gary Telford,

Reduced IFN-γ receptor expression and attenuated IFN-γ response by dendritic cells in patients with atopic dermatitis Eva Gros, MSc, Susanne Petzold,

Differential cytokine induction by the human skin–associated autoallergen thioredoxin in sensitized patients with atopic dermatitis and healthy control.

Accelerated dissociation of IgE-FcεRI complexes by disruptive inhibitors actively desensitizes allergic effector cells Alexander Eggel, PhD, Günther.

Increased expression of nuclear factor of activated T cells 1 drives IL-9–mediated allergic asthma Sonja Koch, PhD, Anna Graser, PhD, Hooman Mirzakhani,

Peanut oral immunotherapy results in increased antigen-induced regulatory T-cell function and hypomethylation of forkhead box protein 3 (FOXP3) Aleena.

Allergen-dependent solubilization of IL-13 receptor α2 reveals a novel mechanism to regulate allergy Michael O. Daines, MD, Weiguo Chen, PhD, Yasuhiro.

FcεRI-mediated amphiregulin production by human mast cells increases mucin gene expression in epithelial cells Shigeru Okumura, DDS, PhD, Hironori Sagara,

Targeting Toll-like receptors on dendritic cells modifies the TH2 response to peanut allergens in vitro Pierre Pochard, PhD, Brian Vickery, MD, M. Cecilia.

Assessing basophil activation by using flow cytometry and mass cytometry in blood stored 24 hours before analysis Kaori Mukai, PhD, Nicolas Gaudenzio,

Omalizumab treatment downregulates dendritic cell FcεRI expression

Birch pollen immunotherapy results in long-term loss of Bet v 1–specific TH2 responses, transient TR1 activation, and synthesis of IgE-blocking antibodies

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy Robert A.

CD19 controls Toll-like receptor 9 responses in human B cells

Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils Henry Lin, MD, Kevin M Boesel, MD, Daniel T Griffith, MD, Calman Prussin,

Basophil FcɛRI histamine release parallels expression of Src-homology 2–containing inositol phosphatases in chronic idiopathic urticaria Becky M. Vonakis,

Toll-like receptor 9 suppression in plasmacytoid dendritic cells after IgE-dependent activation is mediated by autocrine TNF-α John T. Schroeder, PhD,

Vitamin D3 treatment of vitamin D–insufficient asthmatic patients does not alter immune cell function Brandy Reid, MS, Pierre-Olivier Girodet, MD, PhD,

Direct monitoring of basophil degranulation by using avidin-based probes Régis Joulia, PhD, Claire Mailhol, MD, Salvatore Valitutti, MD, Alain Didier,

Kathleen R. Bartemes, BA, Gail M. Kephart, BS, Stephanie J

Thymic stromal lymphopoietin activation of basophils in patients with allergic asthma is IL-3 dependent Brittany M. Salter, BSc, John Paul Oliveria,

Inhibition of FcεRI-dependent mediator release and calcium flux from human mast cells by sialic acid–binding immunoglobulin-like lectin 8 engagement

Food allergy herbal formula 2 protection against peanut anaphylactic reaction is via inhibition of mast cells and basophils Ying Song, MD, Chunfeng Qu,

Mohamed H. Shamji, PhD, Janice A. Layhadi, MSc, Guy W

Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations Raymond G.

Inhibition of human B-cell development into plasmablasts by histone deacetylase inhibitor valproic acid Anne-Kathrin Kienzler, MSc, Marta Rizzi, MD,

Targeting allergen to FcγRI reveals a novel TH2 regulatory pathway linked to thymic stromal lymphopoietin receptor Kathryn E. Hulse, PhD, Amanda J. Reefer,

Loss of syk kinase during IgE-mediated stimulation of human basophils

Mechanisms underlying differential food allergy response to heated egg

Impaired natural killer cell functions in patients with signal transducer and activator of transcription 1 (STAT1) gain-of-function mutations Giovanna.

Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors Donald W. MacGlashan, MD, PhD,

Donald W. MacGlashan, MD, PhD, Sarbjit S. Saini, MD

Decreases in human dendritic cell–dependent TH2-like responses after acute in vivo IgE neutralization John T. Schroeder, PhD, Anja P. Bieneman, BS, Kristin.

Jill A. Poole, MD, Neil E. Alexis, PhD, Conrad Parks, BS, Amy K

Yilin Qi, MSc, Darwin J. Operario, PhD, Christopher M

Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1) Kornvalee Meesilpavikkai,

Prostaglandin E2 resistance in granulocytes from patients with aspirin-exacerbated respiratory disease Tanya M. Laidlaw, MD, Anya J. Cutler, Molly S.

Individual IL-3 priming is crucial for consistent in vitro activation of donor basophils in patients with chronic urticaria Thomas Gentinetta, MSc, Tatjana.

John A. Eckman, MD, Patricia M

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

Oktay Kirak, MD, Gert Riethmüller, MD

Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis Thomas B. Casale, MD, William.

Lipoteichoic acid downregulates FcεRI expression on human mast cells through Toll-like receptor 2 Mino Yoshioka, MSc, Nobuyuki Fukuishi, PhD, Sayuri.

Sarbjit S. Saini, MDa, Jennifer J

Activation of human mast cells through the platelet-activating factor receptor Naoki Kajiwara, PhD, Tomomi Sasaki, BSc, Peter Bradding, DM, Glenn Cruse,

Matthew J. Loza, PhD, Susan Foster, PhD, Stephen P

Sara Paveglio, PhD, MS, Erin Bennett, MS, Kelly L. Hawley, PhD, Adam P

Syk expression and IgE-mediated histamine release in basophils as biomarkers for predicting the clinical efficacy of omalizumab Donald W. MacGlashan,

The steroidogenic enzyme Cyp11a1 is essential for development of peanut-induced intestinal anaphylaxis Meiqin Wang, MD, PhD, Julita Ramirez, DVM, PhD,

Phosphorylation of cytosolic phospholipase A2 by IL-3 is associated with increased free arachidonic acid generation and leukotriene C4 release in human.

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Grass pollen immunotherapy: IL-10 induction and suppression of late responses precedes IgG4 inhibitory antibody activity James N. Francis, PhD, Louisa.

Human basophils may not undergo modulation by DC-SIGN and mannose receptor– targeting immunotherapies due to absence of receptors Mrinmoy Das, MSc, Caroline.

Epicutaneous immunization with ovalbumin and CpG induces TH1/TH17 cytokines, which regulate IgE and IgG2a production Monika Majewska-Szczepanik, PhD,

Functional assessment of pathogenic IgG subclasses in chronic autoimmune urticaria Sridharan Soundararajan, PhD, Yoko Kikuchi, DVM, Kusumam Joseph, PhD,

Fiftieth Annual Meeting of the American Academy of Allergy and Immunology: Anaheim, California, March 1994 Lawrence M. Lichtenstein, MD, PhD Journal.

Combination treatment with omalizumab and rush immunotherapy for ragweed-induced allergic rhinitis: Inhibition of IgE-facilitated allergen binding Sven.

Transforming growth factor β1 increases fibronectin deposition through integrin receptor α5β1 on human airway smooth muscle Lyn M. Moir, PhD, Janette.

Natural history of cow’s milk allergy

CCL17/thymus and activation-regulated chemokine induces calcitonin gene–related peptide in human airway epithelial cells through CCR4 Kandace Bonner,

Presentation transcript:

Regulation of Syk kinase and FcRβ expression in human basophils during treatment with omalizumab Asifa K. Zaidi, PhD, Sarbjit S. Saini, MD, Donald W. MacGlashan, MD, PhD Journal of Allergy and Clinical Immunology Volume 125, Issue 4, Pages 902-908.e7 (April 2010) DOI: 10.1016/j.jaci.2009.12.996 Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 1 Increases in Syk expression and anti-IgE–mediated histamine release in subjects treated with omalizumab. A, Measurement of histamine release induced with an optimal concentration of anti-IgE antibody on pretreatment (day 0, BSL), 4 to 6 weeks after the start of treatment (MID), and 15 weeks (approximately 104 days) after the start of treatment (FINAL) for subjects treated with omalizumab (n = 12). B, Measurement of Syk expression in basophils by means of flow cytometry for the same group of subjects in Fig 1, A. C, Measurement of histamine release induced with anti-IgE antibody in the placebo group (n = 4). D, Measurement of Syk expression by means of flow cytometry in the placebo group. Spontaneous histamine release averaged 3% ± 0.3%. It was not different between groups and did not change during the course of the study. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 2 Kinetics of the increase in anti-IgE antibody–induced histamine release and Syk expression. The data are expressed relative to the pretreatment response or levels of Syk expression (n = 6). Open circles, Histamine release induced by anti-IgE antibody; solid circles, Syk expression measured by means of flow cytometry. Both kinetic curves, taken as a whole, are statistically different than no change (H0 = 1.0, P<0.0001). Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 3 Effect of omalizumab treatment on other IL-3–sensitive characteristics of human basophils. A, The ratio of the measured expression of c-Cbl in purified basophils (as assessed by means of quantitative Western blotting) or the ratio of percentage histamine release induced by 1 μmol/L FMLP. The ratio is calculated as the end point at day 104 (FINAL) divided by the end point before treatment (day 0, BSL). B, Expression of cell-surface FcεRIα and bound IgE levels on peripheral blood basophils from omalizumab- or placebo-treated subjects were determined by means of flow cytometry and Western blotting. The ratio of expression level at day 104 (FINAL) to that before treatment (BSL) is plotted (n = 12, treated with omalizumab; n = 4, treated with placebo agent). C, The ratio of expression of FcRβ and FcεRIα, as determined by means of Western blot analysis of purified blood basophils from omalizumab- or placebo-treated subjects (BSL and FINAL). All data are expressed as means ± SEMs. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Fig 4 Absence of change in FcRβ/FcεRIα ratio in vitro. Purified basophils were cultured in RPMI-1640 with IL-3 (10 ng/mL) for 13 days (D13) either without (NS) or with (S) prior lactic acid treatment to remove endogenously bound IgE. After 13 days of culture, cells were counted and lysed, and lysates were analyzed by using the semiquantitative Western blot procedure used in the omalizumab study to quantitatively assess expression levels. A, Expression of p60, relative to preculture levels (D0) for nonstripped (NS) and stripped (S) cells (n = 5; P = .12 | Ho = 1.0 for nonstripped cells and P = .0005 | Ho = 1.0 for stripped cells). B, Ratio of FcRβ/FcεRIα for day 0 (D0) and nonstripped (NS) and stripped (S) cells on day 13 (D13; n = 5; P = not significant for comparison of 3 groups). Errors shown represent SEMs. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Relationship between the pretreatment level of Syk expression and the fold increase in Syk expression at the FINAL visit (approximately day 104). Each point represents a different subject treated with omalizumab. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Example Western blots. After cutting the nitrocellulose at the 40- and 95-kd line and blotting with 22E7 (for FcεRIα) or anti-FcRβ, the blots were visualized with ECL reagent, and multiple exposures were made. A and B show 2 of 7 exposures for FcεRIα, and C and D show 2 exposures for FcRβ. At the top, S1.0, S0.4, S0.15, and S0.05 are the standard dilutions; C is a control sample; D1 to D3 are donors 1, 2, and 3; V2 is visit 2 (before treatment); and V14 is visit 14 (15 weeks). Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Kinetics of the change in surface IgE and FcεRI expression on peripheral blood basophils during treatment with omalizumab. Cell-surface IgE and FcεRI levels were monitored throughout the treatment. The asterisks over days 30 to 45 in the omalizumab-treated group signify the subset of subjects who were tested at visits later than visit 5 because their histamine release response had not decreased sufficiently to reach the midstudy stopping criterion, and therefore “n” was variable. Surface IgE (open circles) and surface FcεRI (solid circles) levels in the omalizumab group and surface IgE (solid squares) and surface FcεRI (open squares) in the placebo group are shown. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Syk expression in plasmacytoid dendritic cells during treatment with omalizumab. Syk expression was assessed by means of flow cytometry for the omalizumab and placebo treatment groups at pretreatment (day 0, BSL), 4 to 6 weeks after the start of treatment (MID), and 15 weeks (approximately 104 days) after the start of treatment (FINAL) for subjects treated with omalizumab (n = 12) or placebo (n = 4). Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Visual representation of the expression levels of internal and cell-surface receptor subunits. The horizontal columns represent the relative expression of either FcεRIα (p60 or p46) and relative expression of a hypothesized internal and cell-surface FcRβ. The numbers highlighted with a gray background are obtained from the averages of the 12-subject population data. Both the internal and cell-surface columns for FcRβ are variables: x for cell-surface FcRβ, and y for internal FcRβ. In the equation βE is the end-of-treatment FcRβ expression, and βS is the start-of-treatment total FcRβ expression. Journal of Allergy and Clinical Immunology 2010 125, 902-908.e7DOI: (10.1016/j.jaci.2009.12.996) Copyright © 2010 American Academy of Allergy, Asthma & Immunology Terms and Conditions